Axsome Therapeutics (AXSM) Price & Analysis

Compare

2,287 Followers

AXSM Stock Chart & Stats

$147.00

-$0.23(-0.27%)

At close: Jan 08 4:00 PM EST

$147.00

-$0.23(-0.27%)

Day’s Range― - ―

52-Week Range$75.56 - $152.94

Previous CloseN/A

Volume140.83K

Average Volume (3M)500.40K

Market Cap

$7.46B

Enterprise Value$5.97B

Total Cash (Recent Filing)$325.27M

Total Debt (Recent Filing)$218.60M

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Mar 02, 2026

EPS Estimate

-0.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.94

Shares Outstanding50,412,640

10 Day Avg. Volume424,991

30 Day Avg. Volume500,402

Financial Highlights & Ratios

PEG Ratio-1.03

Price to Book (P/B)71.10

Price to Sales (P/S)10.51

P/FCF Ratio-31.50

Enterprise Value/Market Cap0.80

Enterprise Value/Revenue10.63

Enterprise Value/Gross Profit11.58

Enterprise Value/Ebitda-28.11

Forecast

1Y Price Target

$179.17

Price Target Upside21.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)-3.8

Revenue Forecast (FY)$628.76M

Bulls Say, Bears Say

Bulls Say

Drug Development And ApprovalsPotential FDA acceptance of the supplemental new drug application for Auvelity in Alzheimer’s disease-related agitation is anticipated soon.

Market PerformanceAxsome's earnings release indicated that the company narrowly beat top-line expectations, signaling progress towards profitability.

Pipeline ExpansionAxsome announced it will obtain global development and commercialization rights for AZD7325 (BAER-101), a GABA positive allosteric modulator (PAM), through an acquisition of Baergic Bio.

Bears Say

Prescription Data InterpretationAnalysts recommend caution when interpreting weekly prescription data to avoid making definitive judgments about the progress of drug launches.

Prescription TrendsThe Thanksgiving holiday week resulted in a decline in Auvelity prescriptions compared to the previous week.

Regulatory UncertaintyPotential AXS-05 sNDA acceptance from the FDA for treatment of AD-A is a reason for weakness beyond macro pressures.

Axsome Therapeutics News

Strategic Acquisition and Pipeline Expansion Drive Buy Rating for Axsome Therapeutics

William Blair analyst Myles Minter has reiterated their bullish stance on AXSM stock, giving a Buy rating on...

1M ago

AXSM

Avenue Therapeutics announces Baergic Bio acquisition by Axsome

Avenue Therapeutics (ATXI) subsidiary, Baergic Bio announced that Avenue has entered into an agreement for Baergic to be...

1M ago

AZN

ATXI

Axsome enters agreement to obtain exclusive global rights to AZD7325

Axsome Therapeutics (AXSM) (AZXM) entered into an agreement to obtain exclusive global rights to AZD7325, a novel oral...

1M ago

AZN

ATXI

Axsome Therapeutics price target raised to $202 from $200 at Mizuho

Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $202 from $200 and keeps an Outperform...

1M ago

AXSM

Axsome Therapeutics management to meet with Truist

Dinner Meeting to be held in New York on November 5 hosted by Truist. Published first on TheFly...

2M ago

AXSM

Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges

Axsome Therapeutics Inc. (($AXSM)) has held its Q3 earnings call. Read on for the main highlights of the...

2M ago

AXSM

Axsome Therapeutics price target raised to $198 from $189 at RBC Capital

RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $198 from $189 and keeps an...

2M ago

AXSM

Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $185 from $180 and keeps a...

2M ago

AXSM

Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $196 from $194 and keeps an...

2M ago

AXSM

Axsome Therapeutics price target raised to $178 from $176 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $178 from $176 and...

2M ago

AXSM

Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo

Wells Fargo lowered the firm’s price target on Axsome Therapeutics (AXSM) to $157 from $163 and keeps an...

2M ago

AXSM

Axsome Therapeutics Reports Strong Q3 2025 Growth

Axsome Therapeutics Inc. ( ($AXSM) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

AXSM

Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion

TD Cowen analyst Joseph Thome maintained a Buy rating on Axsome Therapeutics yesterday and set a price target...

2M ago

AXSM

Axsome Therapeutics files automatic mixed securities shelf

16:47 EST Axsome Therapeutics (AXSM) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $75.56 and its highest was $152.94 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $7.46B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 72 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on Nov 03, 2025. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.861 by -$0.079.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.73.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 50,412,640 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.861. Following the earnings report the stock price went up 0.563%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-275.50%

Trailing 12-Months

Asset Growth

19.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Axsome Therapeutics reported strong revenue growth and product performance, supported by strategic commercial execution and a robust R&D pipeline. However, increased expenses and ongoing net losses present financial challenges.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$179.17

▲(21.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","113":"$113","143":"$143","173":"$173","203":"$203"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":202,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$202.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$179.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$148.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,113,143,173,203],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.03,153.10461538461539,157.17923076923077,161.25384615384615,165.32846153846154,169.40307692307692,173.4776923076923,177.5523076923077,181.62692307692308,185.70153846153846,189.77615384615385,193.85076923076923,197.92538461538462,{"y":202,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.03,151.34846153846155,153.66692307692307,155.98538461538462,158.30384615384614,160.6223076923077,162.94076923076923,165.25923076923075,167.5776923076923,169.89615384615382,172.21461538461537,174.53307692307692,176.85153846153844,{"y":179.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.03,148.95076923076923,148.87153846153845,148.7923076923077,148.71307692307693,148.63384615384615,148.55461538461537,148.47538461538463,148.39615384615385,148.31692307692308,148.2376923076923,148.15846153846155,148.07923076923078,{"y":148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >